Biorestorative Therapies, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Comparative Q1 2023 figures are identified as restated. The company develops cell-based therapies, including BRTX-100 for disc and spine conditions and the preclinical ThermoStem program. It generated only royalty revenue during the quarter.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $35,000 | $31,300 |
| Research and development expense | $1.06 million | $1.23 million |
| General and administrative expense | $3.09 million | $4.58 million |
| Operating loss | $4.11 million | $5.78 million |
| Net loss | $2.22 million | $7.17 million |
| Net cash used in operations | $2.32 million | $2.38 million |
- Cash and cash equivalents were $1.16 million at March 31, 2024; marketable securities were $15.26 million. Working capital was $13.32 million, versus $8.78 million at December 31, 2023.
- Total liabilities were $3.45 million, including $2.76 million of derivative liabilities and $123,536 of current lease liabilities. The balance sheet reports no conventional borrowings.
- Investing activities used $4.93 million, principally reflecting net purchases of marketable securities. Financing activities provided $7.52 million, mainly from the warrant transaction. Cash increased by $273,000 in the quarter.
Changes versus the prior period
- Revenue increased by $3,700, but remained modest and consisted entirely of royalties under a sublicense agreement.
- Operating expenses fell by $1.67 million. R&D decreased 14%, mainly because Q1 2023 included discretionary bonus costs; G&A declined 33%, primarily due to lower stock-based compensation and headcount costs.
- Net loss improved by $4.95 million. This reflected lower operating expenses, higher interest income, a $1.71 million warrant-exchange gain, and a much smaller fair-value loss on derivative liabilities. The warrant gain is a transaction-related, non-operating item.
- Common shares outstanding rose from 4,706,917 at December 31, 2023 to 6,769,919 at March 31, 2024. A further 1,351,580 exercise shares were held in abeyance pending the holder’s beneficial-ownership limit.
Outlook, risks and unusual items
- Management expects continuing losses and negative operating cash flow as it advances development activities. It believes cash and investments, including warrant proceeds, are sufficient to fund operations for at least 12 months after the financial statements’ issuance, but not to complete development or reach profitability.
- The February warrant transaction generated approximately $8.12 million in gross proceeds and $7.53 million net of issuance costs. It involved exercises at $2.33 per share and new five-year warrants for 2,513,686 shares at $2.43 per share. The new warrants are accounted for as derivative liabilities.
- Management expects R&D expense to increase in subsequent periods. It stated additional financing will eventually be required; inability to obtain it could force the company to curtail development or discontinue operations.
- The company is conducting a Phase 2 BRTX-100 trial and reported that its Data Safety Monitoring Board recommended continuing without changes in June 2023. In April 2024, after quarter-end, the company announced a five-year exclusive supply agreement with Cartessa Aesthetics for its first planned cosmetic product.
- The filing refers to a restatement of previously issued financial statements and presents the comparative Q1 2023 figures as restated. Investors should review the related Form 10-K/A disclosures for details.
- Disclosure controls were deemed ineffective as of March 31, 2024. Material weaknesses included inadequate formal procedures, risk assessment and control testing, and ineffective controls over accounting for warrants. Management described remediation steps, including external accounting support and documenting key controls; the weaknesses had not yet been deemed remediated.
- Key risks include financing needs, clinical and regulatory uncertainty, development and commercialization execution, intellectual-property protection, and the restatement-related control issues. No specific numerical revenue or earnings guidance was provided.
Important facts for investors to verify
- Review the Form 10-K/A and restatement disclosures to understand what was corrected and whether any related control issues remain.
- Track cash burn, investment balances, and financing needs against management’s stated 12-month liquidity assessment.
- Monitor BRTX-100 trial progress, regulatory requirements, and the funding needed to advance the program.
- Assess the dilutive and accounting effects of the new warrants, abeyance shares, stock options, and any further equity financing.
- Verify the status, terms, and commercial contribution of the Cartessa agreement and the planned first product.